Biocardia announces expected cardiamp heart failure japan approval timeline based on pharmaceutical and medical device agency consultation minutes

Sunnyvale, calif., dec. 18, 2023 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that japan pharmaceutical and medical device agency (pmda) minutes support the company's understanding that cardiamp autologous cell therapy may be approved for the treatment of patients with ischemic heart failure with reduced ejection fraction (hfref) based on follow-up data from the patients currently enrolled in the cardiamp heart failure trial (cardiamp hf) that will be available in q4 2024.
BCDA Ratings Summary
BCDA Quant Ranking